Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
about
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsA phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.The changing landscape of phase I trials in oncology.Implementing the EffTox dose-finding design in the Matchpoint trial.Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.Some Geometric Methods for Constructing Decision Criteria Based On Two-Dimensional Parameters.Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas.Recent developments in adaptive designs for Phase I/II dose-finding studies.Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.Dose-finding design driven by efficacy in onco-hematology phase I/II trialsOverall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs
P2860
Q33945668-4AC992D8-6E0F-47B0-A127-FF7E12093AE3Q35296104-C8B2CBBA-5CCC-4416-BCFB-0E8693122BB1Q36913166-9D944E00-5513-43B0-9707-FF741EC9F4C8Q37392513-78BF91E5-8E59-4C63-8BCD-E5140814764CQ37841138-85BA060A-0670-43A5-B23C-F037B849F2D6Q38629203-C9FB7133-9FE4-4B9F-8987-3056F2D8280FQ38654251-06987B46-278F-4E79-BAEF-0072F766D5BCQ38926250-FBF827DA-A72B-4123-AD56-8D184E6529A8Q42200681-F54918C4-EBBC-4DE9-9E5C-5B3298B1B477Q43002849-283A6B29-9CDA-4067-A0A7-75B815FFE6EEQ46700211-E63310F2-9725-4245-BD3C-EDE89873C0F1Q46890429-14CBBC2F-432F-4C00-A937-CA5675FE2749Q46909610-C60C33C0-84F2-4DB4-8EB5-87E75B147469Q50639190-19B424DF-7187-4277-970E-813C044452EDQ55040314-892503BC-45FF-4917-A4AB-68B8323FB5A9Q55123242-37306C7C-743B-4C6C-B78B-9C04B4F54935Q58231326-8D07762A-B691-492A-A06F-054DDC8ADBB2Q58704560-CAB3F8FB-CFA5-407C-88CE-0342E225A6ED
P2860
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adaptive dose selection using ...... and practical considerations.
@ast
Adaptive dose selection using ...... and practical considerations.
@en
type
label
Adaptive dose selection using ...... and practical considerations.
@ast
Adaptive dose selection using ...... and practical considerations.
@en
prefLabel
Adaptive dose selection using ...... and practical considerations.
@ast
Adaptive dose selection using ...... and practical considerations.
@en
P2093
P2860
P1476
Adaptive dose selection using ...... and practical considerations.
@en
P2093
Elihu H Estey
John D Cook
Peter F Thall
P2860
P304
P356
10.1080/10543400600860394
P577
2006-01-01T00:00:00Z